Blog
Revolutionary Gene-Editing Breakthrough: $30m Funding Secured
📰 Eligo Bioscience secures $30m for gene-editing solutions, targeting moderate to severe acne vulgaris and chronic diseases. 💰💉
Former AZ Plant Transformed into Resilience: Thriving in Colorado!
📰 Former AstraZeneca site in Boulder, Colorado transformed into Resilience, a multi-product facility offering flexible process development and more! 💪🏭🔬
Big Shake-Ups in CDMOs: Industry Leaders Revamp
📰 "Ins and Outs: High level changes at CDMOs" discusses recent leadership shifts in the competitive biotech industry. 🔍😯🌍💼⚙️💪📈👥
China Dominates Global Biotech Industry with ADC Partnerships
"📰 China rides high on the ADC partnership wave, capitalizing on global biotech collaborations for biopharmaceutical success. 🚀🌍🧪💼"
Revolutionary Mixing Design Boosts TFF Performance
📰🌷 "Tulip Tank Case Study: The Unrecognized Role of Mixing During TFF" highlights the importance of optimized mixing in bioprocessing. 💡🔬👥
eBook: Strengthening Europe’s Cell and Gene Therapy Sector — Safeguarding the Medicines of the Future
📚 "eBook: Strengthening Europe’s Cell and Gene Therapy Sector — Safeguarding the Medicines of the Future" covers the development process for the biotechnology industry. 🧪 It focuses on upstream and downstream processing, manufacturing, analytical techniques, and business aspects. 💉 The eBook provides insights into the latest advancements and challenges in the European cell and gene therapy sector. 🌍 It aims to ensure the safe and efficient production of future medicines. 🚀
Abselion benchtop tech emerges victorious from UK’s dragon’s den
📰 Abselion benchtop tech emerges victorious from UK’s dragon’s den. Abselion, a benchtop small molecule reaction screening technology, has secured £550k funding on the BBC show. The technology can be used in various industries including pharmaceuticals, agrochemistry, and materials science. The funding will help in scaling up the technology for industrial use. 👨🔬💡
Advanced Technology for Vector-Based Therapies Highlighting Stem Cell-Derived Exosomes Manufacturing Process
📝 The article discusses advanced technology for vector-based therapies and highlights the manufacturing process for stem cell-derived exosomes. 🔬 The manufacturing process involves culturing animal or microbial cells and using controlled feeding, aerating, and process strategies. 💡 This technology has applications in upstream processing, downstream processing, manufacturing, analytical, and business aspects of the biotechnology industry. 🧪 It allows for the removal or reduction of contaminants through centrifugation, filtration, and chromatographic technologies. 🌍 The biopharmaceutical industry is highly entrepreneurial, and partnerships, outsourcing, and licensing agreements are important in navigating the global business environment.
Oxford Biomedica acquires ABL Europe
📰 Oxford Biomedica has acquired ABL Europe, a CDMO specializing in viral vector manufacturing. 🤝 This acquisition will enable Oxford Biomedica to expand its manufacturing capabilities and meet the growing demand for gene and cell therapies. 💼 The deal will also enhance Oxford Biomedica's position as a leading player in the biotech industry. 💪🌍
Kymriah GMP issues in NJ led to FDA letter for Novartis
📰 The FDA has issued a warning letter to Novartis regarding manufacturing issues with their immunotherapy drug Kymriah. 👩⚕️ The letter highlights concerns with the company's quality control procedures and the potential risks to patient safety. 🏭 The issues were identified at a New Jersey facility that produces the therapy. 💊 Novartis has stated that they are working to address the FDA's concerns and ensure the quality and reliability of Kymriah.
